n-(3-4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2-3-dihydroxypropyl)cyclopropane-1-sulfonamide has been researched along with trametinib* in 2 studies
1 review(s) available for n-(3-4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2-3-dihydroxypropyl)cyclopropane-1-sulfonamide and trametinib
| Article | Year |
|---|---|
Targeting the RAS pathway by mitogen-activated protein kinase inhibitors.
Targeting of oncogenic driver mutations with small-molecule inhibitors resulted in powerful treatment options for cancer patients in recent years. The RAS (rat sarcoma) pathway is among the most frequently mutated pathways in human cancer. Whereas targeting mutant Kirsten RAS (KRAS) remains difficult, mutant B rapidly accelerated fibrosarcoma (BRAF) kinase is an established drug target in cancer. Now data show that neuroblastoma RAS (NRAS) and even Harvey RAS (HRAS) mutations could be predictive markers for treatment with mitogen-activated protein kinase (MEK) inhibitors. This review discusses recent preclinical and clinical studies of MEK inhibitors in BRAF and RAS mutant cancer. Topics: Animals; Azetidines; Benzamides; Benzimidazoles; Diphenylamine; Genes, ras; GTP Phosphohydrolases; Humans; Membrane Proteins; Mice; Mitogen-Activated Protein Kinases; Mutation; Neoplasms; Niacinamide; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyridones; Pyrimidinones; Signal Transduction; Sulfonamides | 2015 |
1 other study(ies) available for n-(3-4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2-3-dihydroxypropyl)cyclopropane-1-sulfonamide and trametinib
| Article | Year |
|---|---|
Monosomy 3 Is Linked to Resistance to MEK Inhibitors in Uveal Melanoma.
The use of MEK inhibitors in the therapy of uveal melanoma (UM) has been investigated widely but has failed to show benefits in clinical trials due to fast acquisition of resistance. In this study, we investigated a variety of therapeutic compounds in primary-derived uveal melanoma cell lines and found monosomy of chromosome 3 (M3) and mutations in Topics: Cell Line, Tumor; Chromosomes, Human, Pair 3; Diphenylamine; DNA Copy Number Variations; Drug Resistance, Neoplasm; Eukaryotic Initiation Factor-2; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Melanoma; Mitogen-Activated Protein Kinase Kinases; Monosomy; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Sulfonamides; Survival Analysis; Tumor Suppressor Proteins; Ubiquitin Thiolesterase; Uveal Neoplasms | 2021 |